<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-90190" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Restrictive Lung Disease</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Martinez-Pitre</surname>
            <given-names>Pedro J.</given-names>
          </name>
          <aff>Wyckoff Heights Medical Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Sabbula</surname>
            <given-names>Bhanusivakumar R.</given-names>
          </name>
          <aff>Nassau University Medical Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Cascella</surname>
            <given-names>Marco</given-names>
          </name>
          <aff>Istituto Nazionale Tumori - IRCCS - Fondazione Pascale, Via Mariano Semmola 80100, Napoli. Italy</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Pedro Martinez-Pitre declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Bhanusivakumar Sabbula declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Marco Cascella declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>25</day>
          <month>7</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-90190.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>The purpose of this article is to serve as a brief review of the restrictive lung diseases. The topic is vast, and here, we have provided a concise review of the diseases. This activity reviews the evaluation and management of restrictive lung diseases and highlights the role of the interprofessional team in evaluating and improving care for patients with this condition.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the etiology and epidemiology of restrictive lung diseases.</p></list-item><list-item><p>Explain the appropriate history, physical, and evaluation of restrictive lung diseases.</p></list-item><list-item><p>List the management options available for restrictive lung diseases.</p></list-item><list-item><p>Discuss interprofessional team strategies for improving care coordination and communication to advance restrictive lung disease management and improve outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=90190&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=90190">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-90190.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Restrictive lung diseases are a heterogeneous set of pulmonary disorders defined by restrictive patterns on spirometry. These disorders are characterized by a&#x000a0;reduced distensibility of the lungs, compromising lung expansion, and, in turn, reduced lung volumes, particularly with reduced total lung capacity (TLC).<xref ref-type="bibr" rid="article-90190.r1">[1]</xref>&#x000a0;These functional and other characteristics allow to differentiate them from obstructive pulmonary diseases such as chronic obstructive pulmonary disease (COPD), bronchiectasis, asthma, emphysema, and bronchiolitis characterized by increased resistance to flow&#x000a0;due to obstruction&#x000a0;partial or complete at any level, from the trachea to the terminal bronchioles. In numerical terms, restrictive syndromes account for about a fifth of pulmonary syndromes, while obstructive syndromes are the majority (80%).<xref ref-type="bibr" rid="article-90190.r2">[2]</xref></p>
        <p>Restrictive lung diseases&#x000a0;may be caused by the destruction of distal lung parenchyma due to infiltrates from inflammation, toxins, and mechanisms yet to be elucidated (intrinsic conditions) as well as extra parenchymal conditions (extrinsic causes). Within the former group, there are diseases characterized by inflammatory changes involving&#x000a0;the alveolar interstitium with possible involvement of the&#x000a0;peripheral bronchial structures.&#x000a0;The conditions leading to this destruction are encompassed among the interstitial lung diseases (ILDs). This term refers to an umbrella with numerous disorders that are characterized by diffuse cellular infiltrates in a periacinar location, including clinical conditions that vary from occasional self-limited inflammatory processes to severe debilitating fibrosis of the lungs. Other conditions originate from within the alveolus (e.g., edema, hemorrhage) and spread to interstitial structures.&#x000a0;If the process starts from the interstitium or from the alveolus, in both cases, alteration of the lung architecture, which reverberates into functional impairment occurs.</p>
        <p>On the other hand,&#x000a0;restrictive lung diseases may also result from limitations in neuromuscular function and chest wall movements (extrinsic causes). These may be due to neuromuscular diseases, pleural disorders, obesity, costosternal or costovertebral fusion, a fusion or deviation of the thoracic vertebra, and other etiologies that result in a physical impediment to inspiration.<xref ref-type="bibr" rid="article-90190.r3">[3]</xref>&#x000a0;Regardless of the intrinsic or extrinsic mechanisms, these diseases are featured by impaired ventilatory function and respiratory failure.</p>
        <p>A brief review of the restrictive lung diseases would be discussed. Because the topic is vast, here we have prepared an overview of the disorders, including their diagnosis, treatment, and more.</p>
      </sec>
      <sec id="article-90190.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>The&#x000a0;acronym "PAINT" can be used to memorize the causes of restrictive lung disease into pleural, alveolar, interstitial, neuromuscular, and thoracic cage abnormalities. Nevertheless,&#x000a0;a more accurate division takes into account the pathogenetic mechanism.</p>
        <p>Restrictive lung syndromes can be caused by:</p>
        <list list-type="bullet">
          <list-item>
            <p>Pulmonary parenchyma diseases (intrinsic causes)</p>
          </list-item>
          <list-item>
            <p>Extrapulmonary diseases (extrinsic causes)</p>
          </list-item>
        </list>
        <p>Intrinsic, or pulmonary causes, involve the lung parenchyma itself, while the extrinsic restrictive lung diseases originate from neuromuscular disorders, obesity, and other extra-parenchymal disorders.<xref ref-type="bibr" rid="article-90190.r1">[1]</xref>&#x000a0;In&#x000a0;both intrinsic or extrinsic pulmonary conditions, lung volumes become reduced due to restrictions in&#x000a0;pulmonary mechanics.&#x000a0;</p>
        <p>
<bold>Pulmonary Parenchyma Diseases (Intrinsic Causes)</bold>
</p>
        <p>Intrinsic restriction can be caused by intrapulmonary restriction due to inflammatory processes within the lung tissue by diseases categorized&#x000a0;under interstitial lung diseases.</p>
        <list list-type="bullet">
          <list-item>
            <p>Idiopathic pulmonary fibrosis (IPF)</p>
          </list-item>
          <list-item>
            <p>Non-specific interstitial pneumonia (NSIP)</p>
          </list-item>
          <list-item>
            <p>Cryptogenic organizing pneumonia (COP)</p>
          </list-item>
          <list-item>
            <p>Sarcoidosis</p>
          </list-item>
          <list-item>
            <p>Acute interstitial pneumonia (AIP)</p>
          </list-item>
          <list-item>
            <p>Inorganic dust exposure such as silicosis, asbestosis, talc, pneumoconiosis, berylliosis, hard metal fibrosis, coal worker's pneumoconiosis, chemical worker's lung</p>
          </list-item>
          <list-item>
            <p>Organic dust exposure such as&#x000a0;farmer's lung, bird fancier's lung, bagassosis, and mushroom worker's lung, humidifier lung, hot tub pneumonitis</p>
          </list-item>
          <list-item>
            <p>Hypersensitivity pneumonitis</p>
          </list-item>
          <list-item>
            <p>Systemic sclerosis</p>
          </list-item>
          <list-item>
            <p>Pulmonary vasculitis</p>
          </list-item>
          <list-item>
            <p>Pulmonary Langerhans cell histiocytosis (formerly referred to as histiocytosis X)</p>
          </list-item>
          <list-item>
            <p>Medications such as&#x000a0;nitrofurantoin, amiodarone, gold, phenytoin, thiazides, hydralazine, bleomycin, carmustine, cyclophosphamide, methotrexate</p>
          </list-item>
          <list-item>
            <p>Radiation therapy</p>
          </list-item>
        </list>
        <p>These conditions can be grouped into diseases that lead to an&#x000a0;increased elastic return (e.g., diffuse infiltrative pneumopathies, and interstitial diseases), and diseases provoked by&#x000a0;the occupation of alveolar spaces (e.g., pneumonia).</p>
        <p>
<bold>Extrinsic or Extrapulmonary&#x000a0;Diseases</bold>
</p>
        <p>They&#x000a0;can be a result of diseases of the&#x000a0;chest wall, such as:</p>
        <list list-type="bullet">
          <list-item>
            <p>Kyphoscoliosis</p>
          </list-item>
          <list-item>
            <p>Pleural conditions such as effusions, trapped lung, pleural scarring, chronic empyema, asbestosis</p>
          </list-item>
          <list-item>
            <p>Obesity</p>
          </list-item>
          <list-item>
            <p>Neuromuscular disorders like muscular dystrophy, amyotrophic lateral sclerosis, polio, and phrenic neuropathies.<xref ref-type="bibr" rid="article-90190.r4">[4]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Ascites</p>
          </list-item>
        </list>
        <p>Extrapulmonary diseases&#x000a0;can also be schematically grouped into pathologies that produce&#x000a0;a decreased muscle tone of the respiratory pump (e.g., myopathies, and neurological deficits), deformations of the rib cage (e.g., kyphoscoliosis), and&#x000a0;space occupation (e.g., pleural effusions, pneumothorax).</p>
        <p>In brief, the causes of restrictive diseases can, therefore, be manifold. In some conditions, such as IPF, the causes are unknown. In this context, a challenge concerns the&#x000a0;genetic factors that contribute to disease risk. Kaur et al.<xref ref-type="bibr" rid="article-90190.r5">[5]</xref>, for instance, illustrated the genetics in IPF and correlations with prognosis and treatment. More recently, the role of rare variation in FAM13A, TERT, and RTEL1 gene regions involved in the risk of IPF was demonstrated.<xref ref-type="bibr" rid="article-90190.r6">[6]</xref></p>
      </sec>
      <sec id="article-90190.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>The overall prevalence of restrictive diseases is difficult to&#x000a0;estimate precisely because&#x000a0;the groups involve multiple pathological conditions, each&#x000a0;of which can occur in numerous clinical stages.&#x000a0;It has been determined, however, that up to 3-6 cases per 100,000 persons suffer from intrinsic lung diseases in the United States.<xref ref-type="bibr" rid="article-90190.r7">[7]</xref>&#x000a0;Among the other conditions, the prevalence of sarcoidosis in North&#x000a0;America has been calculated as 10-40 cases per 100,000 persons<xref ref-type="bibr" rid="article-90190.r8">[8]</xref>&#x000a0;with a higher prevalence in&#x000a0;Sweden (64 cases per 100,000 individuals).</p>
        <p>National and global population studies demonstrated that there are certain classes of individuals reported to be at a higher risk for having a restrictive pattern on spirometry. The populations with higher associations to restrictive lung patterns include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Elderly- The prevalence of restrictive conditions increases from 2.7 cases per 100,000 persons in individuals aged 35-44 years&#x000a0;to over 175 cases per 100,000 in those older than 75 years.<xref ref-type="bibr" rid="article-90190.r9">[9]</xref>&#x000a0;Nevertheless,&#x000a0;sarcoidosis, collagen-vascular-associated diseases, and pulmonary Langerhans cell histiocytosis occur in patients aged 20-40 years.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>African Americans- Compared to Whites (10.9 cases per 100,000), the prevalence in this group is 35.5 cases per 100,000 persons.<xref ref-type="bibr" rid="article-90190.r4">[4]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Females- Sarcoidosis is slightly more common in&#x000a0;women. Moreover, the female gender has also been reported an increased risk for a restrictive pattern.<xref ref-type="bibr" rid="article-90190.r10">[10]</xref>&#x000a0;Again, IPF is more common in men than in women.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Obese individuals- Restrictive patterns are related to an elevated body mass index (BMI) with a decrease in lung volumes attributed to an increased amount of central obesity.<xref ref-type="bibr" rid="article-90190.r10">[10]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Smokers<xref ref-type="bibr" rid="article-90190.r4">[4]</xref>- For instance, IPF individuals are usually current or past smokers.</p>
          </list-item>
        </list>
        <p>Those that have specific occupational and environmental exposures are also at increased risk. Frequently encountering substances at workplaces such as asbestos, coal dust, and several other hazardous specks of dust can cause tissue alterations in the lungs leading to inflammation, tissue scarring, and a restrictive pattern on spirometry.<xref ref-type="bibr" rid="article-90190.r10">[10]</xref>&#x000a0;Restrictive lung diseases are a rare occurrence during pregnancy, but if it is present, it is likely due to neuromuscular disease or kyphoscoliosis.<xref ref-type="bibr" rid="article-90190.r11">[11]</xref></p>
        <p>An interesting finding concerns not only the epidemiology of the established pathology but functional subclinical alterations as&#x000a0;well as the temporal evolution. In an epidemiological study, Kurth et al. showed that restrictive patterns on spirometry were found to fall from 7.2% to 5.4% from 1988-1994 and from 2007-2010, which may be related to increased occupational safety precautions and falling rates of cigarette smoking.<xref ref-type="bibr" rid="article-90190.r4">[4]</xref></p>
      </sec>
      <sec id="article-90190.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>The intrinsic pulmonary restriction&#x000a0;is most commonly characterized by inflammation of the pulmonary parenchyma with subsequent deposition of collagen in the interstitium, which ultimately leads to pulmonary fibrosis. Over time, this progressive fibrosis thickens the alveolar septae, imposing a physical barrier to gas exchange. This is reflected in pulmonary function testing (PFT), where&#x000a0;decreased diffusing capacity for carbon dioxide (DLCO) can be observed.<xref ref-type="bibr" rid="article-90190.r1">[1]</xref><xref ref-type="bibr" rid="article-90190.r12">[12]</xref>&#x000a0;Besides decreasing DLCO, lung tissue fibrosis decreases&#x000a0;the compliance of the lung tissue, reducing the inspiratory capacity.<xref ref-type="bibr" rid="article-90190.r13">[13]</xref>&#x000a0;</p>
        <p>The pathophysiology of extrapulmonary forms provides an altered mechanical function very often induced by&#x000a0;deformations of the rib cage, but also linked to neurological or muscular pathologies, or&#x000a0;from the occupation of space, as in the case of pleural effusions.</p>
        <p>
<bold>The Compliance</bold>
</p>
        <p>The distensibility of the respiratory system is termed as&#x000a0;compliance (C).&#x000a0;It&#x000a0;a key concept in respiratory physiology and represents the volume change produced by a change in the distending pressure. It is determined by elastic forces formula:</p>
        <p>
<italic toggle="yes">C=&#x00394;V/&#x00394;P</italic>
</p>
        <p>Of note, lung compliance is independent of the thoracic cage, which is a semirigid casing, but lung and thorax are systems arranged in series.&#x000a0;Thus, the compliance of an intact respiratory system is the sum of the compliances of both of these structures. Therefore, it is affected by any disease of the lungs, pleura, or chest wall.&#x000a0;Lung&#x000a0;compliance decreases if the lung is over&#x000a0;rigid (restrictive pathologies) and increases in&#x000a0;less stiff conditions such as emphysema.&#x000a0;Thoracic&#x000a0;compliance decreases in conditions of reduced distensibility of the&#x000a0;rib cage (obesity, kyphoscoliosis). Combined compliance of thorax and lungs is 110 ml/cmH2O, whereas the&#x000a0;compliance of lung alone is approximately 200 ml/cmH2O.&#x000a0;Decreased compliance, either from intrapulmonary or extrapulmonary etiology, results in greater pressure generation and energy requirements from the respiratory muscles for any given tidal volume.<xref ref-type="bibr" rid="article-90190.r13">[13]</xref>&#x000a0;These&#x000a0;changes in respiratory physiology eventually lead to tissue hypoxia and dyspnea.</p>
        <p>
<bold>Hypoxemia</bold>
</p>
        <p>Hypoxemia (PaO2&#x0003c;60 mmHg), whether or not in association with hypercapnia (PaCO2&#x0003e;45 mmHg), can be a consequence of lung damage, and an expression of respiratory failure. In restrictive syndromes, it occurs with different mechanisms depending on the type of the disease. In the intrinsic conditions, it is produced by alterations in the gas diffusion with a&#x000a0;mismatch in the ventilation-perfusion ratio. This process leads, in turn, to an increased intrapulmonary shunt that is the portion of the pulmonary blood flow that bypasses the alveoli or perfuses unventilated alveoli and does not participate in the gas exchanges. On the other hand, hypoventilation and pump failure are prominent in the extrinsic conditions.</p>
        <p>
<bold>Functional Characteristics </bold>
</p>
        <p>Functional characteristics of a restrictive pattern in pulmonary function tests (PFTs) include decreased TLC and forced vital capacity (FVC). This latter parameter is the&#x000a0;maximum amount of air exhaled after a maximal inhalation and depends on the elasticity of the lung tissue, the anatomy of the thoracic cage, and the function of the respiratory muscles. According to the American Thoracic Society (ATS), the TLC predicted (adjusted for gender, age, height) value can be used for assessing the severity of the restrictive condition:<xref ref-type="bibr" rid="article-90190.r14">[14]</xref><xref ref-type="bibr" rid="article-90190.r15">[15]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>TLC &#x0003c; 80% = Restrictive disease</p>
          </list-item>
          <list-item>
            <p>70-80 % predicted: mild restrictive disease</p>
          </list-item>
          <list-item>
            <p>60-70% predicted: moderate restrictive&#x000a0;disease</p>
          </list-item>
          <list-item>
            <p>50-60% predicted: moderately severe restrictive&#x000a0;disease</p>
          </list-item>
          <list-item>
            <p>&#x0003c; 50% predicted: severe restrictive&#x000a0;disease</p>
          </list-item>
        </list>
        <p>Of note, in restrictive diseases, the forced expiratory volume over 1 second (FEV1) usually slightly decreases or stays normal, and the ratio of FEV1 to FVC is generally preserved or increased. These alterations&#x000a0;in pulmonary dynamics can be compensated by an increased respiratory rate, with hypercapnia developing only at later stages of the disease.<xref ref-type="bibr" rid="article-90190.r16">[16]</xref>&#x000a0;</p>
        <p>The functional data are different from those observed in obstructive syndromes in which&#x000a0;TLC&#x000a0;and FVC are&#x000a0;normal (80-120% of&#x000a0;predicted) or increased, while the significant figure is the decrease in the FEV1 compared to&#x000a0;FCV.</p>
        <p>In summary, the patterns&#x000a0;in PFTs in the two groups of respiratory disease are:</p>
        <p>Restrictive Patterns:&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Decreased FVC and TLC</p>
          </list-item>
          <list-item>
            <p>FEV1 is usually slightly decreased or stays normal</p>
          </list-item>
          <list-item>
            <p>The ratio of FEV1 to FVC is usually preserved or increased.</p>
          </list-item>
          <list-item>
            <p>Reduced&#x000a0;DLCO</p>
          </list-item>
        </list>
        <p>Obstructive Patterns:</p>
        <list list-type="bullet">
          <list-item>
            <p>TLC&#x000a0;and&#x000a0;FCV are normal or increased</p>
          </list-item>
          <list-item>
            <p>Decreased FEV1 compared to FCV</p>
          </list-item>
          <list-item>
            <p>The ratio of FEV1 to FVC is&#x000a0;decreased</p>
          </list-item>
          <list-item>
            <p>Reduced&#x000a0;DLCO in emphysema, normal in chronic bronchitis, normal or increased in asthma</p>
          </list-item>
        </list>
        <p>There are also combined obstructive and restrictive patterns, usually featuring low or normal FVC, low FEV1, and a lower&#x000a0;FEV1 to FVC ratio and with a decreased, normal, or increased TLC.</p>
      </sec>
      <sec id="article-90190.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>Lesions that determine intrinsic interstitial diseases originate from lesions of the alveolar capillaries with protein exudation, hemorrhage, and accumulation of inflammatory elements in the alveolar spaces. Alternatively, edema and interstitial inflammatory infiltration may occur. Interstitial fibrosis represents the consequence of both previous processes.&#x000a0;Beyond a didactic schematism, the histopathological findings are manifold; some of those more specific, while others can be found in different conditions.</p>
        <p>
<bold>Usual Interstitial Pneumonia and Idiopathic Pulmonary Fibrosis</bold>
</p>
        <p>The morphological pattern of the&#x000a0;usual interstitial pneumonia (UIP) identifies&#x000a0;a set of modifications of the pulmonary microstructure&#x000a0;characterized by the alternation of areas of a normal lung with&#x000a0;fibrotic areas and prevalent subpleural and paraseptal distribution. Although this picture describes IPF,&#x000a0;it is not exclusive to IPF alone but can also be detected in other clinical entities. Indeed, although the term UIP is often used interchangeably with IPF, other clinical conditions can show the pathological findings of UIP. In particular, IPF is a specific form of chronic fibrosing interstitial pneumopathy, an&#x000a0;unknown etiology (idiopathic UIP) where the alveolitis produces fibroblast&#x000a0;proliferation and collagen deposition. Accurate histopathological analysis, however, can identify distinctive elements. One of the main characteristics of the&#x000a0;UIP/IPF pattern is&#x000a0;the temporal heterogeneity of fibrosis.&#x000a0;This peculiar aspect is represented by the coexistence of&#x000a0;dense scar areas of mature collagen fibrosis&#x000a0;and "honeycomb" areas, and&#x000a0;young fibroblastic proliferation called fibroblastic foci. Furthermore, in the IPF, a polypoid proliferation of myofibroblasts, generally&#x000a0;protruding into alveolar or bronchiolar cavities, characterized by a stroma with scarce collagen fibers, can be observed.&#x000a0;The interstitial septa appear fibrotic and coated with hyperplastic type 2 pneumocytes or with&#x000a0;epithelium in bronchiolar metaplasia with a hyperplastic aspect.</p>
        <p>
<bold>Non-Specific Interstitial Pneumonia</bold>
</p>
        <p>It has histological and radiological characteristics different from all the other&#x000a0;interstitial diseases&#x000a0;of unknown etiology.&#x000a0;It is essential to know its&#x000a0;morphologic and clinic&#x000a0;features as,&#x000a0;compared to IPF, this disease manifests a much better prognosis. Morphologically, there are changes in lung architecture that do not fully meet the criteria&#x000a0;which underlie the other forms of pulmonary interstitial disease.&#x000a0;Three subgroups of the NSIP pattern can be recognized:</p>
        <list list-type="bullet">
          <list-item>
            <p>Cellular Pattern:&#x000a0;A&#x000a0;mild to moderate chronic inflammatory&#x000a0;interstitial infiltrate, mainly represented by lymphocytes and plasma cells,&#x000a0;occasionally arranged in nodular aggregates</p>
          </list-item>
          <list-item>
            <p>Fibrous Pattern: Scarce cellular elements with a greater fibrous component</p>
          </list-item>
          <list-item>
            <p>Mixed Pattern: Coexistence of the two forms</p>
          </list-item>
        </list>
        <p>
<bold>Cryptogenic Organizing Pneumonia</bold>
</p>
        <p>The morphological pattern often shows a bronchiolocentric location with the maintenance of the pulmonary architecture in&#x000a0;the areas surrounding the remodeling process.&#x000a0;The morphological characteristics are the proliferation of connective tissue (Masson bodies) inside&#x000a0;of the small airways and alveolar ducts,&#x000a0;with occlusion of the bronchioles (obliterating bronchiolitis) and surrounding alveoli (organized pneumonia).</p>
        <p>
<bold>Sarcoidosis</bold>
</p>
        <p>It is a multisystemic inflammatory disease that begins more&#x000a0;frequently between 20 and 40 years of age and represents the most frequent of all interstitial lung diseases. The lungs are almost constantly affected (about 90% of cases) with bilateral pulmonary hilar lymph node involvement and&#x000a0;possible simultaneous involvement of the lungs. Histopathology features include noncaseating epithelioid granulomas with tightly packed epithelioid&#x000a0;cells, Langhans giant cells, and T lymphocytes. These findings are localized&#x000a0;in interstitium adjacent to bronchioles as well as around and within&#x000a0;vessel walls, pleura, and connective tissue septa. There are Schaumann bodies (laminated concretions of calcium and protein) and&#x000a0;asteroid elements (stellate inclusions within giant cells).</p>
      </sec>
      <sec id="article-90190.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>A comprehensive history and thorough physical examination&#x000a0;are required to identify and classify these complex disorders appropriately. A careful history-taker must be sure to include inquisition as to the severity of symptoms, time course/origin of symptoms, rate of worsening of symptoms, family history, smoking and drug history, as well as occupational and environmental exposure history.<xref ref-type="bibr" rid="article-90190.r3">[3]</xref> Each condition has its own set of signs and symptoms which are unique to the particular disease and its pathophysiology. However, most are characterized by an insidious progression of dyspnea.<xref ref-type="bibr" rid="article-90190.r13">[13]</xref>&#x000a0;Moreover, ILDs&#x000a0;classically produce the "3Cs": cough, clubbing of the nails, and coarse crackles on auscultation.<xref ref-type="bibr" rid="article-90190.r17">[17]</xref></p>
        <p>Common additional characteristics in patients with extrinsic restriction will include an increased BMI, spine deviation, or have a history of neuromuscular disease.</p>
        <p>Clinical features and prognosis vary among the diseases. For instance, IPF involves a progressive decline in lung function that leads to eventual respiratory failure. As a consequence, the condition has a poor prognosis with a median survival of 3&#x000a0;to 5&#x02009;years after diagnosis.</p>
      </sec>
      <sec id="article-90190.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>The mainstay for evaluation for pulmonary restriction is based on pulmonary function tests (PFTs). Initial results indicative of pulmonary restriction will be a decreased TLC with a preserved FEV1/FVC ratio (greater than 70%). Once restrictive, a restrictive pattern is suggested on spirometry; patients should be referred for full PFTs with DLCO measurement, which will be decreased on patients with intrinsic pulmonary restriction.<xref ref-type="bibr" rid="article-90190.r18">[18]</xref>&#x000a0;Patients with extrinsic pulmonary restriction will also present with a restrictive pattern on PFTs; however, DLCO remains normal.<xref ref-type="bibr" rid="article-90190.r19">[19]</xref> Additional testing with high resolution computed tomography (HRCT), inflammatory markers, and specific autoantibodies should be done on an individual basis according to the suspected etiology of the pulmonary restriction.</p>
        <p>In the IPF, the high-resolution computerized tomography (HRTC) demonstrates the typical appearance with coarse crosslinking in the basal regions, posterior in the&#x000a0;early stages, peripheral/sub-pleural.&#x000a0;"Honeycomb" cystic alterations and bronchiectasis that become evident for traction&#x000a0;fibrotic.</p>
        <p>A special type among the ILDs is idiopathic pulmonary fibrosis. Guidelines from the ATS suggests considering adult patients with newly detected&#x000a0;bilateral fibrosis on a chest radiograph&#x000a0;or chest CT, bibasilar&#x000a0;inspiratory crackles, and an age typically older&#x000a0;than 60 years of an unknown cause, to be&#x000a0;clinically suspected for having IPF.<xref ref-type="bibr" rid="article-90190.r15">[15]</xref></p>
      </sec>
      <sec id="article-90190.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Management of restrictive lung disease varies depending on the etiology of the restriction. Patients diagnosed with IPF have been traditionally treated with immunosuppression; however, new anti-fibrotic drugs such as pirfenidone and nintedanib are increasingly used as they have shown to slow down disease progression.<xref ref-type="bibr" rid="article-90190.r20">[20]</xref>&#x000a0;Patients with autoimmune conditions that can lead to interstitial lung diseases like systemic sclerosis are being treated with immunosuppressant drugs, including steroids, mycophenolate mofetil, and cyclophosphamide depending on the degree of disease.<xref ref-type="bibr" rid="article-90190.r21">[21]</xref>&#x000a0;</p>
        <p>Patients with acute exacerbations are usually treated with steroids over&#x000a0;several days; however, prolonged steroid therapy is not recommended due to their associated complications.<xref ref-type="bibr" rid="article-90190.r22">[22]</xref>&#x000a0;Oxygen therapy, managing comorbid conditions, and pulmonary rehabilitation, in addition to pirfenidone and nintedanib, are prescribed as treatments suggested for idiopathic pulmonary fibrosis.<xref ref-type="bibr" rid="article-90190.r1">[1]</xref><xref ref-type="bibr" rid="article-90190.r23">[23]</xref>&#x000a0;For obese patients, management involves losing weight by a combination of diet and physical exercise.<xref ref-type="bibr" rid="article-90190.r3">[3]</xref>&#x000a0;Morbidly obese patients who fail to lose weight by traditional methods should be referred for gastric bypass surgery evaluation as it has been shown effective in achieving significant weight loss and improvement on PFTs.<xref ref-type="bibr" rid="article-90190.r24">[24]</xref>&#x000a0;Impairment in pulmonary function in patients with severe scoliosis may be controlled with surgical correction.<xref ref-type="bibr" rid="article-90190.r25">[25]</xref> Patients with extensive pulmonary fibrosis and chronic respiratory failure should be&#x000a0;evaluated as possible candidates&#x000a0;for lung transplantation.<xref ref-type="bibr" rid="article-90190.r26">[26]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-90190.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>The differential diagnosis of pulmonary restriction remains broad even after it has been diagnosed by PFTs as there are several causes of pulmonary restriction. Intrinsic pulmonary restriction can be caused by any of the interstitial lung diseases&#x000a0;such as</p>
        <list list-type="bullet">
          <list-item>
            <p>Idiopathic pulmonary fibrosis</p>
          </list-item>
          <list-item>
            <p>Non-specific interstitial pneumonia</p>
          </list-item>
          <list-item>
            <p>Cryptogenic organizing pneumonia</p>
          </list-item>
          <list-item>
            <p>Acute interstitial pneumonia</p>
          </list-item>
          <list-item>
            <p>Pneumoconiosis</p>
          </list-item>
          <list-item>
            <p>Hypersensitivity pneumonitis</p>
          </list-item>
          <list-item>
            <p>Systemic sclerosis</p>
          </list-item>
          <list-item>
            <p>Sarcoidosis</p>
          </list-item>
        </list>
        <p>Causes of extrinsic pulmonary restriction include</p>
        <list list-type="bullet">
          <list-item>
            <p>Obesity</p>
          </list-item>
          <list-item>
            <p>Spinal deviation</p>
          </list-item>
          <list-item>
            <p>Neuromuscular disorders</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-90190.s11" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>The prognosis of patients with restrictive lung disease&#x000a0;varies greatly depending on the etiology of pulmonary restriction. Patients with pulmonary restriction from a pleural effusion should experience resolution of symptoms upon drainage, and pregnant patients should also recover upon delivery. Intrinsic pulmonary restriction from cryptogenic organizing pneumonia&#x000a0;is associated with excellent long term outcomes when treated. Patients diagnosed with IPF have a median survival of 3-5 years after diagnosis.<xref ref-type="bibr" rid="article-90190.r27">[27]</xref><xref ref-type="bibr" rid="article-90190.r28">[28]</xref>&#x000a0;Acute interstitial pneumonia has a grave prognosis as it is associated with greater than 70% mortality in 3 months.<xref ref-type="bibr" rid="article-90190.r29">[29]</xref><bold>&#x000a0;</bold>Due to the diverse nature of restrictive lung disease, all efforts should be made to obtain a specific diagnosis once pulmonary restriction has been confirmed.&#x000a0;</p>
      </sec>
      <sec id="article-90190.s12" sec-type="Complications">
        <title>Complications</title>
        <p>Advanced restrictive lung disease results in&#x000a0;hypoxemia, which can only be compensated by elevations in respiratory rate. Increased energy expenditure in breathing can lead to muscle wasting and weight loss. Once compensatory mechanisms fail, and hypoxia worsens, patients develop chronic respiratory failure. Sleep disorders, including obstructive sleep apnea (OSA), which are common in patients with extrinsic pulmonary restriction due to obesity, have also been noted in a significant amount of patients with intrinsic&#x000a0;restrictive lung disease.<xref ref-type="bibr" rid="article-90190.r30">[30]</xref>&#x000a0;Chronic respiratory failure and lung architecture distortion lead to pulmonary hypertension and cor-pulmonale.</p>
      </sec>
      <sec id="article-90190.s13" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>After identification of the etiology of the pulmonary restriction, patients should be oriented on the treatment options available for them. For patients with progressive disease, pulmonary rehabilitation centers aid in counseling patients about their breathing and oxygen needs as well as teach exercises that can improve respiratory function and mitigate symptoms. At times, exercise and weight loss can prove effective, especially when obesity is the main factor leading to pulmonary restriction.</p>
      </sec>
      <sec id="article-90190.s14" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>The management of restrictive lung diseases can often be complex and challenging due to the many diseases that can result in the condition. For a primary care provider, knowing when to refer a patient to a pulmonologist can be extremely beneficial to the patient. Because of the long list of differential diagnoses and the complications of different conditions, a multidisciplinary approach is always recommended. Besides the primary care provider and pulmonologist, the team would also include nurses who would periodically assess the patients as well as internists and intensivists who would provide care in the inpatient setting according to the severity of the patient's condition.</p>
        <p>Cardiology evaluation should be obtained, especially if pulmonary restriction&#x000a0;leads to signs of&#x000a0;heart strain as it can potentially result in heart failure. Pharmacists are to be part of the team whenever specialty medications, including the newer anti-fibrotic agents, are used. Nutritionists should also be included in cases of obesity, and Neurologists should be involved in cases of neuromuscular disease. Transplant surgeons ought to assess end-stage patients who are candidates for transplant. Palliative and hospice care specialists should also be involved in cases where there is a terminal disease.</p>
      </sec>
      <sec id="article-90190.s15">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=90190&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=90190">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/lung-disease-respiratory-health/restrictive-lung-disease/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=90190">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/90190/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=90190">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-90190.s16">
        <title>References</title>
        <ref id="article-90190.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Robinson</surname>
                <given-names>HC</given-names>
              </name>
            </person-group>
            <article-title>Respiratory Conditions Update: Restrictive Lung Disease.</article-title>
            <source>FP Essent</source>
            <year>2016</year>
            <month>Sep</month>
            <volume>448</volume>
            <fpage>29</fpage>
            <page-range>29-34</page-range>
            <pub-id pub-id-type="pmid">27576233</pub-id>
          </element-citation>
        </ref>
        <ref id="article-90190.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mangera</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Panesar</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Makker</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Practical approach to management of respiratory complications in neurological disorders.</article-title>
            <source>Int J Gen Med</source>
            <year>2012</year>
            <volume>5</volume>
            <fpage>255</fpage>
            <page-range>255-63</page-range>
            <pub-id pub-id-type="pmid">22505823</pub-id>
          </element-citation>
        </ref>
        <ref id="article-90190.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fiorentino</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Esquinas</surname>
                <given-names>AM</given-names>
              </name>
            </person-group>
            <article-title>Restrictive lung disease: Low EPAP - Good ventilation. Is it real?</article-title>
            <source>Chron Respir Dis</source>
            <year>2017</year>
            <month>Aug</month>
            <volume>14</volume>
            <issue>3</issue>
            <fpage>321</fpage>
            <page-range>321-322</page-range>
            <pub-id pub-id-type="pmid">28393535</pub-id>
          </element-citation>
        </ref>
        <ref id="article-90190.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kurth</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Hnizdo</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Change in prevalence of restrictive lung impairment in the U.S. population and associated risk factors: the National Health and Nutrition Examination Survey (NHANES) 1988-1994 and 2007-2010.</article-title>
            <source>Multidiscip Respir Med</source>
            <year>2015</year>
            <volume>10</volume>
            <issue>1</issue>
            <fpage>7</fpage>
            <pub-id pub-id-type="pmid">25745559</pub-id>
          </element-citation>
        </ref>
        <ref id="article-90190.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kaur</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mathai</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Schwartz</surname>
                <given-names>DA</given-names>
              </name>
            </person-group>
            <article-title>Genetics in Idiopathic Pulmonary Fibrosis Pathogenesis, Prognosis, and Treatment.</article-title>
            <source>Front Med (Lausanne)</source>
            <year>2017</year>
            <volume>4</volume>
            <fpage>154</fpage>
            <pub-id pub-id-type="pmid">28993806</pub-id>
          </element-citation>
        </ref>
        <ref id="article-90190.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Moore</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Blumhagen</surname>
                <given-names>RZ</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>IV</given-names>
              </name>
              <name>
                <surname>Walts</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Powers</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Walker</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Bishop</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Russell</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Vestal</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Cardwell</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Markin</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>Mathai</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Schwarz</surname>
                <given-names>MI</given-names>
              </name>
              <name>
                <surname>Steele</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>KK</given-names>
              </name>
              <name>
                <surname>Loyd</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Crapo</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Silverman</surname>
                <given-names>EK</given-names>
              </name>
              <name>
                <surname>Cho</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>James</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Guthridge</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Cogan</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Kropski</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Swigris</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Bair</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Ji</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Song</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Maier</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Pacheco</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Hirani</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Poon</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Jenkins</surname>
                <given-names>RG</given-names>
              </name>
              <name>
                <surname>Braybrooke</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Saini</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Maher</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Molyneaux</surname>
                <given-names>PL</given-names>
              </name>
              <name>
                <surname>Saunders</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Gibson</surname>
                <given-names>KF</given-names>
              </name>
              <name>
                <surname>Kass</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Rojas</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sembrat</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wolters</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Collard</surname>
                <given-names>HR</given-names>
              </name>
              <name>
                <surname>Sundy</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>O'Riordan</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Strek</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Noth</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Ma</surname>
                <given-names>SF</given-names>
              </name>
              <name>
                <surname>Porteous</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Kreider</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>NB</given-names>
              </name>
              <name>
                <surname>Inoue</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Hirose</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Arai</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Akagawa</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Eickelberg</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Fernandez</surname>
                <given-names>IE</given-names>
              </name>
              <name>
                <surname>Behr</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mogulkoc</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Corte</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Glaspole</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Tomassetti</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ravaglia</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Poletti</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Crestani</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Borie</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kannengiesser</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Parfrey</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Fiddler</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Rassl</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Molina-Molina</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Machahua</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Worboys</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Gudmundsson</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Isaksson</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Lederer</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Podolanczuk</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Montesi</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Bendstrup</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Danchel</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Selman</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pardo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Henry</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Keane</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Doran</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Va&#x00161;&#x000e1;kov&#x000e1;</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sterclova</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ryerson</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Wilcox</surname>
                <given-names>PG</given-names>
              </name>
              <name>
                <surname>Okamoto</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Furusawa</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Miyazaki</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Laurent</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Baltic</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Prele</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Moodley</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Shea</surname>
                <given-names>BS</given-names>
              </name>
              <name>
                <surname>Ohta</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Suzukawa</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Narumoto</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Nathan</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Venuto</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Woldehanna</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Kokturk</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>de Andrade</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Luckhardt</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kulkarni</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Bonella</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Donnelly</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>McElroy</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Armstong</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Aranda</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Carbone</surname>
                <given-names>RG</given-names>
              </name>
              <name>
                <surname>Puppo</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Beckman</surname>
                <given-names>KB</given-names>
              </name>
              <name>
                <surname>Nickerson</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Fingerlin</surname>
                <given-names>TE</given-names>
              </name>
              <name>
                <surname>Schwartz</surname>
                <given-names>DA</given-names>
              </name>
            </person-group>
            <article-title>Resequencing Study Confirms That Host Defense and Cell Senescence Gene Variants Contribute to the Risk of Idiopathic Pulmonary Fibrosis.</article-title>
            <source>Am J Respir Crit Care Med</source>
            <year>2019</year>
            <month>Jul</month>
            <day>15</day>
            <volume>200</volume>
            <issue>2</issue>
            <fpage>199</fpage>
            <page-range>199-208</page-range>
            <pub-id pub-id-type="pmid">31034279</pub-id>
          </element-citation>
        </ref>
        <ref id="article-90190.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hutchinson</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hubbard</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Raghu</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Surgical lung biopsy for interstitial lung disease: when considered necessary, should these be done in larger and experienced centres only?</article-title>
            <source>Eur Respir J</source>
            <year>2019</year>
            <month>Feb</month>
            <volume>53</volume>
            <issue>2</issue>
            <pub-id pub-id-type="pmid">30792236</pub-id>
          </element-citation>
        </ref>
        <ref id="article-90190.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Burke</surname>
                <given-names>RR</given-names>
              </name>
              <name>
                <surname>Stone</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Havstad</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Rybicki</surname>
                <given-names>BA</given-names>
              </name>
            </person-group>
            <article-title>Racial differences in sarcoidosis granuloma density.</article-title>
            <source>Lung</source>
            <year>2009</year>
            <season>Jan-Feb</season>
            <volume>187</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-7</page-range>
            <pub-id pub-id-type="pmid">18716835</pub-id>
          </element-citation>
        </ref>
        <ref id="article-90190.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Esposito</surname>
                <given-names>DB</given-names>
              </name>
              <name>
                <surname>Lanes</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Donneyong</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Holick</surname>
                <given-names>CN</given-names>
              </name>
              <name>
                <surname>Lasky</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Lederer</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Nathan</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>O'Quinn</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Parker</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Tran</surname>
                <given-names>TN</given-names>
              </name>
            </person-group>
            <article-title>Idiopathic Pulmonary Fibrosis in United States Automated Claims. Incidence, Prevalence, and Algorithm Validation.</article-title>
            <source>Am J Respir Crit Care Med</source>
            <year>2015</year>
            <month>Nov</month>
            <day>15</day>
            <volume>192</volume>
            <issue>10</issue>
            <fpage>1200</fpage>
            <page-range>1200-7</page-range>
            <pub-id pub-id-type="pmid">26241562</pub-id>
          </element-citation>
        </ref>
        <ref id="article-90190.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mannino</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>McBurnie</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Tan</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Kocabas</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Anto</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Vollmer</surname>
                <given-names>WM</given-names>
              </name>
              <name>
                <surname>Buist</surname>
                <given-names>AS</given-names>
              </name>
              <collab>BOLD Collaborative Research Group</collab>
            </person-group>
            <article-title>Restricted spirometry in the Burden of Lung Disease Study.</article-title>
            <source>Int J Tuberc Lung Dis</source>
            <year>2012</year>
            <month>Oct</month>
            <volume>16</volume>
            <issue>10</issue>
            <fpage>1405</fpage>
            <page-range>1405-11</page-range>
            <pub-id pub-id-type="pmid">22863565</pub-id>
          </element-citation>
        </ref>
        <ref id="article-90190.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lapinsky</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Tram</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Mehta</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Maxwell</surname>
                <given-names>CV</given-names>
              </name>
            </person-group>
            <article-title>Restrictive lung disease in pregnancy.</article-title>
            <source>Chest</source>
            <year>2014</year>
            <month>Feb</month>
            <volume>145</volume>
            <issue>2</issue>
            <fpage>394</fpage>
            <page-range>394-398</page-range>
            <pub-id pub-id-type="pmid">24493511</pub-id>
          </element-citation>
        </ref>
        <ref id="article-90190.r12">
          <label>12</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Modi</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Cascella</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <chapter-title>Diffusing Capacity of the Lungs for Carbon Monoxide</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>3</month>
            <day>13</day>
            <pub-id pub-id-type="pmid">32310609</pub-id>
          </element-citation>
        </ref>
        <ref id="article-90190.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Laveneziana</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Qualitative aspects of exertional dyspnea in patients with restrictive lung disease.</article-title>
            <source>Multidiscip Respir Med</source>
            <year>2010</year>
            <month>Jun</month>
            <day>30</day>
            <volume>5</volume>
            <issue>3</issue>
            <fpage>211</fpage>
            <page-range>211-5</page-range>
            <pub-id pub-id-type="pmid">22958444</pub-id>
          </element-citation>
        </ref>
        <ref id="article-90190.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Aggarwal</surname>
                <given-names>AN</given-names>
              </name>
              <name>
                <surname>Agarwal</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>The new ATS/ERS guidelines for assessing the spirometric severity of restrictive lung disease differ from previous standards.</article-title>
            <source>Respirology</source>
            <year>2007</year>
            <month>Sep</month>
            <volume>12</volume>
            <issue>5</issue>
            <fpage>759</fpage>
            <page-range>759-62</page-range>
            <pub-id pub-id-type="pmid">17875068</pub-id>
          </element-citation>
        </ref>
        <ref id="article-90190.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hariri</surname>
                <given-names>LP</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Mino-Kenudson</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Allen</surname>
                <given-names>TC</given-names>
              </name>
              <name>
                <surname>Attanoos</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Borczuk</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Burke</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Cagle</surname>
                <given-names>PT</given-names>
              </name>
              <name>
                <surname>Capelozzi</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Dacic</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Guinee</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Raparia</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Roden</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Roy-Chowdhuri</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sholl</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Beasley</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Churg</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Pulmonary Pathology Society Perspective on the 2018 American Thoracic Society, European Respiratory Society, Japanese Respiratory Society, and Latin American Thoracic Society Idiopathic Pulmonary Fibrosis Clinical Practice Guidelines.</article-title>
            <source>Ann Am Thorac Soc</source>
            <year>2020</year>
            <month>May</month>
            <volume>17</volume>
            <issue>5</issue>
            <fpage>550</fpage>
            <page-range>550-554</page-range>
            <pub-id pub-id-type="pmid">31945306</pub-id>
          </element-citation>
        </ref>
        <ref id="article-90190.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Faverio</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>De Giacomi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Bonaiti</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Stainer</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sardella</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Pellegrino</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Sferrazza Papa</surname>
                <given-names>GF</given-names>
              </name>
              <name>
                <surname>Bini</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Bodini</surname>
                <given-names>BD</given-names>
              </name>
              <name>
                <surname>Carone</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Annoni</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Messinesi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Pesci</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Management of Chronic Respiratory Failure in Interstitial Lung Diseases: Overview and Clinical Insights.</article-title>
            <source>Int J Med Sci</source>
            <year>2019</year>
            <volume>16</volume>
            <issue>7</issue>
            <fpage>967</fpage>
            <page-range>967-980</page-range>
            <pub-id pub-id-type="pmid">31341410</pub-id>
          </element-citation>
        </ref>
        <ref id="article-90190.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wallis</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Spinks</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>The diagnosis and management of interstitial lung diseases.</article-title>
            <source>BMJ</source>
            <year>2015</year>
            <month>May</month>
            <day>07</day>
            <volume>350</volume>
            <fpage>h2072</fpage>
            <pub-id pub-id-type="pmid">25952322</pub-id>
          </element-citation>
        </ref>
        <ref id="article-90190.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Johnson</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Theurer</surname>
                <given-names>WM</given-names>
              </name>
            </person-group>
            <article-title>A stepwise approach to the interpretation of pulmonary function tests.</article-title>
            <source>Am Fam Physician</source>
            <year>2014</year>
            <month>Mar</month>
            <day>01</day>
            <volume>89</volume>
            <issue>5</issue>
            <fpage>359</fpage>
            <page-range>359-66</page-range>
            <pub-id pub-id-type="pmid">24695507</pub-id>
          </element-citation>
        </ref>
        <ref id="article-90190.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zammit</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Liddicoat</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Moonsie</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Makker</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Obesity and respiratory diseases.</article-title>
            <source>Int J Gen Med</source>
            <year>2010</year>
            <month>Oct</month>
            <day>20</day>
            <volume>3</volume>
            <fpage>335</fpage>
            <page-range>335-43</page-range>
            <pub-id pub-id-type="pmid">21116339</pub-id>
          </element-citation>
        </ref>
        <ref id="article-90190.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Belloli</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Beckford</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Hadley</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Flaherty</surname>
                <given-names>KR</given-names>
              </name>
            </person-group>
            <article-title>Idiopathic non-specific interstitial pneumonia.</article-title>
            <source>Respirology</source>
            <year>2016</year>
            <month>Feb</month>
            <volume>21</volume>
            <issue>2</issue>
            <fpage>259</fpage>
            <page-range>259-68</page-range>
            <pub-id pub-id-type="pmid">26564810</pub-id>
          </element-citation>
        </ref>
        <ref id="article-90190.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yasuoka</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Recent Treatments of Interstitial Lung Disease with Systemic Sclerosis.</article-title>
            <source>Clin Med Insights Circ Respir Pulm Med</source>
            <year>2015</year>
            <volume>9</volume>
            <issue>Suppl 1</issue>
            <fpage>97</fpage>
            <page-range>97-110</page-range>
            <pub-id pub-id-type="pmid">26819563</pub-id>
          </element-citation>
        </ref>
        <ref id="article-90190.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kishaba</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Acute Exacerbation of Idiopathic Pulmonary Fibrosis.</article-title>
            <source>Medicina (Kaunas)</source>
            <year>2019</year>
            <month>Mar</month>
            <day>16</day>
            <volume>55</volume>
            <issue>3</issue>
            <pub-id pub-id-type="pmid">30884853</pub-id>
          </element-citation>
        </ref>
        <ref id="article-90190.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Naji</surname>
                <given-names>NA</given-names>
              </name>
              <name>
                <surname>Connor</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Donnelly</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>McDonnell</surname>
                <given-names>TJ</given-names>
              </name>
            </person-group>
            <article-title>Effectiveness of pulmonary rehabilitation in restrictive lung disease.</article-title>
            <source>J Cardiopulm Rehabil</source>
            <year>2006</year>
            <season>Jul-Aug</season>
            <volume>26</volume>
            <issue>4</issue>
            <fpage>237</fpage>
            <page-range>237-43</page-range>
            <pub-id pub-id-type="pmid">16926688</pub-id>
          </element-citation>
        </ref>
        <ref id="article-90190.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ardila-Gatas</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sharma</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Nor Hanipah</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Tu</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Brethauer</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Aminian</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tolle</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Schauer</surname>
                <given-names>PR</given-names>
              </name>
            </person-group>
            <article-title>Bariatric surgery in patients with interstitial lung disease.</article-title>
            <source>Surg Endosc</source>
            <year>2019</year>
            <month>Jun</month>
            <volume>33</volume>
            <issue>6</issue>
            <fpage>1952</fpage>
            <page-range>1952-1958</page-range>
            <pub-id pub-id-type="pmid">30367295</pub-id>
          </element-citation>
        </ref>
        <ref id="article-90190.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Johari</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sharifudin</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Ab Rahman</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Omar</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Abdullah</surname>
                <given-names>AT</given-names>
              </name>
              <name>
                <surname>Nor</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lam</surname>
                <given-names>WC</given-names>
              </name>
              <name>
                <surname>Yusof</surname>
                <given-names>MI</given-names>
              </name>
            </person-group>
            <article-title>Relationship between pulmonary function and degree of spinal deformity, location of apical vertebrae and age among adolescent idiopathic scoliosis patients.</article-title>
            <source>Singapore Med J</source>
            <year>2016</year>
            <month>Jan</month>
            <volume>57</volume>
            <issue>1</issue>
            <fpage>33</fpage>
            <page-range>33-8</page-range>
            <pub-id pub-id-type="pmid">26831315</pub-id>
          </element-citation>
        </ref>
        <ref id="article-90190.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sulica</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Teirstein</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Padilla</surname>
                <given-names>ML</given-names>
              </name>
            </person-group>
            <article-title>Lung transplantation in interstitial lung disease.</article-title>
            <source>Curr Opin Pulm Med</source>
            <year>2001</year>
            <month>Sep</month>
            <volume>7</volume>
            <issue>5</issue>
            <fpage>314</fpage>
            <page-range>314-22</page-range>
            <pub-id pub-id-type="pmid">11584182</pub-id>
          </element-citation>
        </ref>
        <ref id="article-90190.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Baha</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Y&#x00131;ld&#x00131;r&#x00131;m</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>K&#x000f6;kt&#x000fc;rk</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Galata</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Aky&#x000fc;rek</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Demirci</surname>
                <given-names>NY</given-names>
              </name>
              <name>
                <surname>T&#x000fc;rkta&#x0015f;</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Cryptogenic and Secondary Organizing Pneumonia: Clinical Presentation, Radiological and Laboratory Findings, Treatment, and Prognosis in 56 Cases.</article-title>
            <source>Turk Thorac J</source>
            <year>2018</year>
            <month>Oct</month>
            <volume>19</volume>
            <issue>4</issue>
            <fpage>201</fpage>
            <page-range>201-208</page-range>
            <pub-id pub-id-type="pmid">30322441</pub-id>
          </element-citation>
        </ref>
        <ref id="article-90190.r28">
          <label>28</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Chandra</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Maini</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Hershberger</surname>
                <given-names>DM</given-names>
              </name>
            </person-group>
            <chapter-title>Cryptogenic Organizing Pneumonia</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2022</year>
            <month>9</month>
            <day>12</day>
            <pub-id pub-id-type="pmid">29939651</pub-id>
          </element-citation>
        </ref>
        <ref id="article-90190.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bouros</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Nicholson</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Polychronopoulos</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>du Bois</surname>
                <given-names>RM</given-names>
              </name>
            </person-group>
            <article-title>Acute interstitial pneumonia.</article-title>
            <source>Eur Respir J</source>
            <year>2000</year>
            <month>Feb</month>
            <volume>15</volume>
            <issue>2</issue>
            <fpage>412</fpage>
            <page-range>412-8</page-range>
            <pub-id pub-id-type="pmid">10706513</pub-id>
          </element-citation>
        </ref>
        <ref id="article-90190.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mavroudi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Papakosta</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Kontakiotis</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Domvri</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kalamaras</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Zarogoulidou</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Zarogoulidis</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Latka</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Hohenforst-Schmidt</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Zarogoulidis</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Sleep disorders and health-related quality of life in patients with interstitial lung disease.</article-title>
            <source>Sleep Breath</source>
            <year>2018</year>
            <month>May</month>
            <volume>22</volume>
            <issue>2</issue>
            <fpage>393</fpage>
            <page-range>393-400</page-range>
            <pub-id pub-id-type="pmid">29038949</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
